The quality, safety, and efficacy requirements of proprietary industrially-prepared medicinal products derived from human blood or plasma were ensured through Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use(5). The specific exclusion of whole blood, plasma and blood cells of human origin from that Directive, however, has led to a situation whereby their quality and safety, in so far as they are intended for transfusion and not processed as such, are not subject to any binding Community legislation. It is essential, therefore, that whatever the intended purpose, Community provisions should ensure that blood and its components are of comparable quality and safety throughout the blood transfusion chain in all Member States, bearing in mind the freedom of movement of citizens within Community territory. The establishment of high standards of quality and safety, therefore, will help to reassure the public that human blood and blood components which are derived from donations in another Member State nonetheless meet the same requirements as those in their own country.
Recital 3, Directive (EU) 2002/98
Judgment of the Court (First Chamber), 13 March 2014. Octapharma France SAS v Agence nationale de sécurité du médicament et des produits de Decision
Recitals 2, 3, and 5 in the preamble to Directive 2002/98 state: The availability of blood and blood components used for therapeutic purposes is dependent largely on Community citizens who are prepared to donate. In order to safeguard …
13 Mar 2014 · 62012CJ0512
Opinion of Advocate General Mengozzi delivered on 17 July 2014. Geoffrey Léger v Ministre des Affaires sociales, de la Santé et des Droits dDecision
Its adoption is part of a context in which the Member States had previously experienced failings in their systems for monitoring and securing the transfusion chain. Consequently, the supranational authorities took up the matter, at the …
17 Jul 2014 · 62013CC0528
Opinion of Advocate General Jääskinen delivered on 7 November 2013. Octapharma France SAS v Agence nationale de sécurité du médicament et deDecision
Recital 3 of Directive 2002/98 states that the ‘quality, safety and efficacy requirements of proprietary industrially-prepared medicinal products derived from human blood or plasma were ensured through Directive 2001/83 …’ but adds …
7 Nov 2013 · 62012CC0512